Clinical trial
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
NCT00140348 · Cell Genesys, Industry · Completed
Key facts
| NCT number | NCT00140348 |
|---|---|
| Title | Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine |
| Official title | A Phase I/II Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine in Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Lead sponsor | Cell Genesys, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | Immunotherapy allogeneic GM-CSF secreting cellular vaccine |
| Enrollment | 80 |
| Start date | Dec 1, 2001 |
| Completion | Apr 1, 2005 |
| First posted | Sep 1, 2005 |
| Last update posted | Dec 24, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: